Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Rhea-AI Summary

Aclarion (Nasdaq: ACON, ACONW) announced a second commercial agreement with Weill Cornell Medicine to expand clinical use of its Nociscan platform in a prospective randomized trial led by Roger Härtl, MD (IRB Protocol No. 24-09027977). The study will assess lumbar microdiscectomy with or without intradiscal bone marrow aspirate concentrate (BMAC) over two years, measuring patient-reported outcomes, intervertebral disc health, and pain biomarkers. Aclarion says Nociscan quantifies chemical biomarkers linked to disc pain and reports a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.

News Market Reaction – ACON

-3.32%

1 alert

-3.32% Session close to close

$8.15M Market Cap

0.0x Rel. Volume

In the May 5 session, ACON declined 3.32%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Aclarion’s second commercial agreement with Weill Cornell Medicine, int...

Analysis

This announcement highlights Aclarion’s second commercial agreement with Weill Cornell Medicine, integrating Nociscan into a 2-year randomized controlled trial on lumbar microdiscectomy and bone marrow aspirate concentrate. It reinforces prior themes of building clinical evidence and adoption around Nociscan’s reported 97% surgical success rate and addressing a global cLBP population of 266 million. Investors may track enrollment progress, outcome data, and how such collaborations contribute to broader commercial uptake.

Key Figures

Study duration: 2-year prospective study IRB protocol number: 24-09027977 Global cLBP population: 266 million people +1 more

4 metrics

Study duration 2-year prospective study Lumbar microdiscectomy with/without BMAC injection trial

IRB protocol number 24-09027977 Weill Cornell randomized controlled trial identifier

Global cLBP population 266 million people Worldwide degenerative spine disease and low back pain estimate

Surgical success rate 97% When all Nociscan-identified pain positive discs are treated

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Q1 2026 earnings	Positive	+1.8%	Reported strong Q1 with 196% YoY and 64% sequential scan growth.
Apr 28	Leadership hire	Positive	+0.0%	Appointed Commercial Director for Western U.S. to drive Nociscan adoption.
Apr 22	Share repurchase	Positive	+10.8%	Announced $2.5M stock repurchase program funded with existing cash.
Apr 16	Patent grant	Positive	+3.8%	Secured U.S. patent for machine learning analysis of MRS data in Nociscan.
Apr 14	AI award	Positive	-1.3%	Received AI innovation award recognizing Nociscan’s clinical decision platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally seen positive alignment between favorable announcements and share price, with one instance of positive news followed by a negative reaction.

Recent Company History

Over the past month, Aclarion has reported multiple positive developments, including a $2.5M stock repurchase plan, strong Q1 2026 results with 196% scan volume growth, and expansion of its AI-driven Nociscan platform and patent portfolio. Most of these announcements were followed by modest to strong price gains, though an AI innovation award on Apr 14 saw a slight negative move. Today’s Weill Cornell trial agreement continues the theme of clinical adoption and evidence-building around Nociscan.

Key Terms

bone marrow aspirate concentrate, intradiscal, intervertebral disc, degenerative disc disease, +4 more

8 terms

bone marrow aspirate concentrate medical

"with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection"

Bone marrow aspirate concentrate (BMAC) is a medical product made by drawing a small amount of bone marrow, spinning it down to concentrate the cells and factors involved in tissue repair, and returning or using that concentrated material in a patient. Investors track BMAC because its safety, clinical evidence, regulatory classification, and reimbursement determine market size and sales potential—think of it as squeezing a fruit to make a concentrated juice whose demand depends on proof it works and rules about how it can be sold.

intradiscal medical

"with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection"

Describes a treatment, device or procedure that is applied directly inside an intervertebral disc — the cushioning pad between spinal bones. Think of it as putting medicine or a tiny implant into the center of a car tire rather than around it: it’s highly targeted. For investors, “intradiscal” signals a specialized spine product or therapy with specific clinical, regulatory and reimbursement hurdles and a focused patient market, which can affect development cost, approval timeline and commercial potential.

intervertebral disc medical

"intervertebral disc (IVD) health (tissue hydration & composition)"

An intervertebral disc is the soft, flexible cushion sitting between the bones of the spine that absorbs shock and lets the spine bend and twist, like a small shock absorber or rubber pad separating stacked blocks. It matters to investors because many medical products and treatments—implants, surgical procedures, biologic therapies and imaging tools—target disc damage or degeneration, so advances, approvals or clinical setbacks can directly affect company value and market opportunity.

degenerative disc disease medical

"learn more about the natural history of degenerative disc disease (DDD)"

Degenerative disc disease is the gradual breakdown of the soft, cushion-like discs between spinal bones, which can cause chronic back or neck pain and reduced mobility. Like the worn-out shock absorbers on a car, failing discs lead to compensating repairs and replacements, creating sustained demand for treatments such as medications, medical devices, surgeries and rehabilitation; that demand, regulatory approvals and long-term care costs are what make the condition important to investors.

biomarkers medical

"and pain biomarkers in a 2-year prospective study"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

randomized controlled trial medical

"a Prospective Randomized Controlled Trial,” conducted under IRB Protocol No. 24-09027977"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

irb regulatory

"conducted under IRB Protocol No. 24-09027977"

An Institutional Review Board (IRB) is an independent committee that reviews and approves medical and behavioral research involving people to ensure safety, informed consent, and ethical treatment—think of it as a safety inspector for studies. For investors, IRB decisions matter because their approval or requests for changes can speed up, delay, or halt clinical trials and other studies, directly affecting timelines, costs, and the value of companies developing treatments.

saas technical

"the first evidence-supported SaaS platform to noninvasively help physicians"

SaaS, or Software as a Service, is a way of delivering computer programs over the internet, allowing users to access and use them through a web browser without needing to install or maintain the software themselves. For investors, it highlights a business model where companies generate recurring revenue by providing ongoing access to their software, often leading to predictable income and growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expands use of Nociscan in groundbreaking trial with Roger Härtl, MD

BROOMFIELD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan^® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Härtl, MD, the founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian. The trial is entitled “Bone Marrow Aspirate Concentrate Injection with MRI's - a Prospective Randomized Controlled Trial,” conducted under IRB Protocol No. 24-09027977.

The purpose of this study is to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection on patient reported outcomes, intervertebral disc (IVD) health (tissue hydration & composition), and pain biomarkers in a 2-year prospective study. The aim is to learn more about the natural history of degenerative disc disease (DDD), its causes, and inform its treatments.

“Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine,” said Roger Härtl, MD, the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at Weill Cornell Medicine in New York, who serves as a paid consultant for Aclarion. “This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging.”

This is the second trial at Weill Cornell Medicine to incorporate use of Nociscan.

“We are pleased to engage in this trial with Dr. Härtl and his team at Weill Cornell,” said Ryan Bond, Chief Strategy Officer of Aclarion. “Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain.¹ Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success² rate when all Nociscan-identified pain positive discs are treated.

For more News from Aclarion, please visit: Latest News

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

References:
1. Ravindra VM, Global Spine Journal (2018) 8(8): 784-794, AO Spine.
2. Gornet M, Peacock J, et al. European Spine Journal. 2019; 28:674-687.

FAQ

What is the Weill Cornell trial using Nociscan (ACON) testing?

The trial evaluates lumbar microdiscectomy with or without intradiscal BMAC over two years. According to the company, it measures patient-reported outcomes, IVD tissue hydration and composition, and pain biomarkers to study degenerative disc disease.

Where will Aclarion's Nociscan be used under the new ACON agreement?

Nociscan will be used at Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell. According to the company, the deployment supports a prospective randomized controlled trial led by Roger Härtl, MD.

Who is leading the Nociscan (ACON) study at Weill Cornell?

The study is led by neurosurgeon Roger Härtl, MD, founder/director of Weill Cornell Center for Comprehensive Spine Care. According to the company, Dr. Härtl serves as a paid consultant for Aclarion and is principal on the trial.

What outcomes will the Nociscan (ACON) trial measure over two years?

The trial will track patient-reported outcomes, intervertebral disc health (hydration and composition), and pain-related chemical biomarkers. According to the company, these measures aim to clarify the natural history and treatment effects in degenerative disc disease.

What evidence does Aclarion (ACON) cite for Nociscan's clinical value?

The company states Nociscan noninvasively quantifies chemical biomarkers associated with disc pain and reports a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated. According to the company, Nociscan is an evidence-supported SaaS diagnostic platform.